Cybin reports second quarter financial results and recent business highlights

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended september 30, 2023, and recent business highlights. “advancing our clinical programs with the goal of changing the treatment landscape in mental health has.
CYBN Ratings Summary
CYBN Quant Ranking